Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Current trials: The significant phase 3 clinical program assessing the efficacy and safety of semaglutide (SUSTAIN) in type 2 diabetes has been completed
Tirzepatide (Zepbound/Mounjaro) has demonstrated greater weight loss efficacy in clinical trials, with patients losing up to 22.5% of body weight compared to 15% to 17% with semaglutide
E.DarceyT.NkilizaA.KeeganA
The timeline for seeing results with GLP-1 receptor agonists varies from person to person and depends on factors such as starting weight, adherence to treatment, diet, exercise, and overall health
US$ 22.52
US$ 22.13
US$ 24.47
US$ 29.47
US$ 27.59
US$ 23.10
US$ 25.25
US$ 20.96
US$ 27.94
US$ 23.40
